AstraZeneca PLC / Spirogen Limited

Oncology — Antibody-Drug Conjugate (ADC) Platform Targeting Hematologic & Solid Tumors

Disease Overview

Antibody-drug conjugates couple a tumor-targeting monoclonal antibody to a cytotoxic 'warhead' via a chemical linker, aiming to deliver chemotherapy selectively to cancer cells. The class breakthrough came with Adcetris (2011) and Kadcyla (2013), which validated targeted payload delivery — but next-generation warheads with higher potency and better therapeutic indices were the strategic prize.

Competitive Landscape

By October 2013 the ADC field had two approved drugs (Seattle Genetics/Takeda's Adcetris, brentuximab vedotin, MMAE warhead; and Roche/Genentech's Kadcyla, T-DM1, maytansine warhead) and a deepening pipeline using auristatin and maytansinoid warheads. Spirogen's pyrrolobenzodiazepine (PBD) dimer warheads represented a structurally distinct, more potent class — DNA minor-groove cross-linkers active at low picomolar concentrations and active in MMAE-resistant settings. PBDs had drawn industry interest before AstraZeneca: Spirogen had partnerships with Genentech (2011) and ADC Therapeutics (2012), and PBD payloads later powered Pfizer's Mylotarg relabel (gemtuzumab ozogamicin uses calicheamicin, but PBDs powered subsequent Pfizer/AbbVie/ADCT programs including Zynlonta/loncastuximab tesirine). MedImmune paid $200M upfront + up to $240M milestones (total $440M) for 100% of Spirogen plus a co-development pact and equity investment in ADC Therapeutics covering breast, lung, prostate, renal and hematologic cancer ADCs. The deal positioned MedImmune to internalize a differentiated payload platform under Pascal Soriot's stated oncology pivot — a thesis later vindicated by AstraZeneca's ADC franchise (Enhertu via Daiichi partnership 2019, Datroway 2025) and the broader PBD class proliferation through ADC Therapeutics' Zynlonta approval (2021).